Back to search results

Reduced-Dose Radiation for Metastatic Tumors with ATM Mutation

This study is exploring if a lower dose of palliative radiotherapy (radiation treatment to relieve symptoms) can effectively treat metastatic tumors (cancers that have spread) in people who have a specific genetic change called an ATM mutation. Researchers want to find the lowest effective radiation dose. To join, you must have a confirmed cancer that has spread, an ATM mutation, and be at least 18 years old. The study will measure how well the treatment works by looking at the treatment failure rate of the irradiated tumor for up to 12 months. The current status of this study is unclear, and it plans to enroll 45 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 45 participants.
What's involved
Participants will receive palliative radiotherapy (4Gy x 2) and will be re-evaluated at 2 and 6 months (+/- 2 weeks).
Compensation
Not stated in the trial record.
Follow-up
The study will measure treatment failure rate for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05010031

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~45 participants
Updated 2026-05-11 on ClinicalTrials.gov
What's tested:Palliative radiotherapy

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment failure rate of irradiated lesion
Measured over up to 12 months

Conditions

Metastatic Cancer

Explore related trials

Solid NeoplasmATM Gene

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Amy Xu, MD, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Amy Xu, MD, PhD
[email protected]
646-888-6863
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
Pathogenic mutation in ATM (somatic and germline allowed)
ECOG performance status 0-2
Age ≥ 18 years.
Able to provide informed consent.
Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.
Expected life expectancy of at least 6 months

Exclusion

Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
Serious medical co-morbidities precluding radiotherapy.
Pregnant or breast-feeding women.
Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.

What this trial measures

  • Treatment failure rate of irradiated lesionup to 12 months

    Defined as (i) radiographic progression or (ii) re-irradiation to the treated site. If PET is performed, radiographic criteria will be evaluated per PERCIST